Escape Bio
SOUTH SAN FRANCISCO, CA · Founded 2015 · CIK 0001651573 · Biotech · Defunct
LRRK2 kinase inhibitors
escapebio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $124M
- 3 Form D · Sep 2020
- 73 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 16
- 2 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $20,002,700 | |
| Private capital raised | Form D · SEC | $31,073,380 | |
| Private capital raised | Form D · SEC | $73,000,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1249 | Tooth Bank, LLC | — | $200K |
| 1250 | EnLiven Therapeutics | — | $140M |
| 1251 | Seurat Therapeutics, Inc. | — | $773K |
| 1252 | Escape Bio | — | $124M |
| 1253 | B-TECH CONSULTING, LTD | — | — |
| 1254 | MIND BIOSCIENCES LLC | — | — |
| 1255 | TScan Therapeutics | — | $123M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Carrolee BarlowExecutive Officer
- Laura BrassDirector
- Leon ChenDirector · Executive Officer
- Giovanni FerarraDirector
- Giovanni FerraraDirector
- Markus GoebelDirector
- Perry KarsenDirector
- Judith LiDirector
- Peter MoldtDirector
- Anthony RimacExecutive Officer
- Eric ShiozakiDirector
- Julie SmithDirector · Executive Officer
- Peter ThompsonDirector
- R WilliamsDirector
- R. WilliamsDirector
- R. Sanders WilliamsDirector
- Paul WrenExecutive Officer
- Asish XavierDirector
Patents
- Solid Forms Of An S1P-RECEPTOR Modulatorapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
- Solid Forms Of An S1P-RECEPTOR Modulatorgranted
- Indazoles And Azaindazoles As LRRK2 Inhibitorsgranted
- Indazoles As LRRK2 Inhibitorsapplication
- Processes For Preparing An S1P-RECEPTOR Modulatorapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
- Indazoles As LRRK2 Inhibitorsapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
- Indazoles And Azaindazoles As LRRK2 Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.